|
1
|
Hartgrink HH, Jansen EP, van Grieken NC
and van de Velde CJ: Gastric cancer. Lancet. 374:477–490. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kamangar F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality, and prevalence across five
continents: Defining priorities to reduce cancer disparities in
different geographic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wu WK, Lee CW, Cho CH, Fan D, Wu K, Yu J
and Sung JJ: MicroRNA dysregulation in gastric cancer: A new player
enters the game. Oncogene. 29:5761–5771. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rana TM: Illuminating the silence:
Understanding the structure and function of small RNAs. Nat Rev Mol
Cell Biol. 8:23–36. 2007. View
Article : Google Scholar
|
|
5
|
Valencia-Sanchez MA, Liu J, Hannon GJ and
Parker R: Control of translation and mRNA degradation by miRNAs and
siRNAs. Genes Dev. 20:515–524. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pillai RS, Bhattacharyya SN and Filipowicz
W: Repression of protein synthesis by miRNAs: How many mechanisms?
Trends Cell Biol. 17:118–126. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Thomson JM, Newman M, Parker JS,
Morin-Kensicki EM, Wright T and Hammond SM: Extensive
post-transcriptional regulation of microRNAs and its implications
for cancer. Genes Dev. 20:2202–2207. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Esquela-Kerscher A and Slack FJ: Oncomirs
- microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schetter AJ, Leung SY, Sohn JJ, Zanetti
KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, et
al: MicroRNA expression profiles associated with prognosis and
therapeutic outcome in colon adenocarcinoma. JAMA. 299:425–436.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Garzon R, Volinia S, Liu CG,
Fernandez-Cymering C, Palumbo T, Pichiorri F, Fabbri M, Coombes K,
Alder H, Nakamura T, et al: MicroRNA signatures associated with
cytogenetics and prognosis in acute myeloid leukemia. Blood.
111:3183–3189. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xu J, Wu C, Che X, Wang L, Yu D, Zhang T,
Huang L, Li H, Tan W, Wang C, et al: Circulating microRNAs, miR-21,
miR-122, and miR-223, in patients with hepatocellular carcinoma or
chronic hepatitis. Mol Carcinog. 50:136–142. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yaman Agaoglu F, Kovancilar M, Dizdar Y,
Darendeliler E, Holdenrieder S, Dalay N and Gezer U: Investigation
of miR-21, miR-141, and miR-221 in blood circulation of patients
with prostate cancer. Tumour Biol. 32:583–588. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lawrie CH, Gal S, Dunlop HM, Pushkaran B,
Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J,
Wainscoat JS, et al: Detection of elevated levels of
tumour-associated microRNAs in serum of patients with diffuse large
B-cell lymphoma. Br J Haematol. 141:672–675. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Resnick KE, Alder H, Hagan JP, Richardson
DL, Croce CM and Cohn DE: The detection of differentially expressed
microRNAs from the serum of ovarian cancer patients using a novel
real-time PCR platform. Gynecol Oncol. 112:55–59. 2009. View Article : Google Scholar
|
|
17
|
Qiu S, Lin S, Hu D, Feng Y, Tan Y and Peng
Y: Interactions of miR-323/miR-326/miR-329 and
miR-130a/miR-155/miR-210 as prognostic indicators for clinical
outcome of glioblastoma patients. J Transl Med. 11(10)2013.
View Article : Google Scholar
|
|
18
|
Ratert N, Meyer HA, Jung M, Lioudmer P,
Mollenkopf HJ, Wagner I, Miller K, Kilic E, Erbersdobler A, Weikert
S, et al: miRNA profiling identifies candidate miRNAs for bladder
cancer diagnosis and clinical outcome. J Mol Diagn. 15:695–705.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ishihara K, Sasaki D, Tsuruda K, Inokuchi
N, Nagai K, Hasegawa H, Yanagihara K and Kamihira S: Impact of
miR-155 and miR-126 as novel biomarkers on the assessment of
disease progression and prognosis in adult T-cell leukemia. Cancer
Epidemiol. 36:560–565. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sand M, Skrygan M, Sand D, Georgas D, Hahn
SA, Gambichler T, Altmeyer P and Bechara FG: Expression of
microRNAs in basal cell carcinoma. Br J Dermatol. 167:847–855.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu SG, Qin XG, Zhao BS, Qi B, Yao WJ,
Wang TY, Li HC and Wu XN: Differential expression of miRNAs in
esophageal cancer tissue. Oncol Lett. 5:1639–1642. 2013.PubMed/NCBI
|
|
22
|
Zhang X, Huang L, Zhao Y and Tan W:
Downregulation of miR-130a contributes to cisplatin resistance in
ovarian cancer cells by targeting X-linked inhibitor of apoptosis
(XIAP) directly. Acta Biochim Biophys Sin. 45:995–1001. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xu N, Shen C, Luo Y, Xia L, Xue F, Xia Q
and Zhang J: Upregulated miR-130a increases drug resistance by
regulating RUNX3 and Wnt signaling in cisplatin-treated HCC cell.
Biochem Biophys Res Commun. 425:468–472. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huang B, Qu Z, Ong CW, Tsang YH, Xiao G,
Shapiro D, Salto-Tellez M, Ito K, Ito Y and Chen LF: RUNX3 acts as
a tumor suppressor in breast cancer by targeting estrogen receptor
α. Oncogene. 31:527–534. 2012. View Article : Google Scholar
|
|
25
|
Kim WJ, Kim EJ, Jeong P, Quan C, Kim J, Li
QL, Yang JO, Ito Y and Bae SC: RUNX3 inactivation by point
mutations and aberrant DNA methylation in bladder tumors. Cancer
Res. 65:9347–9354. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Araki K, Osaki M, Nagahama Y, Hiramatsu T,
Nakamura H, Ohgi S and Ito H: Expression of RUNX3 protein in human
lung adenocarcinoma: Implications for tumor progression and
prognosis. Cancer Sci. 96:227–231. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li QL, Ito K, Sakakura C, Fukamachi H,
Inoue K, Chi XZ, Lee KY, Nomura S, Lee CW, Han SB, et al: Causal
relationship between the loss of RUNX3 expression and gastric
cancer. Cell. 109:113–124. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hsu PI, Hsieh HL, Lee J, Lin LF, Chen HC,
Lu PJ and Hsiao M: Loss of RUNX3 expression correlates with
differentiation, nodal metastasis, and poor prognosis of gastric
cancer. Ann Surg Oncol. 16:1686–1694. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kundu J, Wahab SM, Kundu JK, Choi YL,
Erkin OC, Lee HS, Park SG and Shin YK: Tob1 induces apoptosis and
inhibits proliferation, migration and invasion of gastric cancer
cells by activating Smad4 and inhibiting β-catenin signaling. Int J
Oncol. 41:839–848. 2012.PubMed/NCBI
|
|
30
|
Fukamachi H: Runx3 controls growth and
differentiation of gastric epithelial cells in mammals. Dev Growth
Differ. 48:1–13. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cheng HC, Liu YP, Shan YS, Huang CY, Lin
FC, Lin LC, Lee L, Tsai CH, Hsiao M and Lu PJ: Loss of RUNX3
increases osteo-pontin expression and promotes cell migration in
gastric cancer. Carcinogenesis. 34:2452–2459. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Schaefer A, Jung M, Mollenkopf HJ, Wagner
I, Stephan C, Jentzmik F, Miller K, Lein M, Kristiansen G and Jung
K: Diagnostic and prognostic implications of microRNA profiling in
prostate carcinoma. Int J Cancer. 126:1166–1176. 2010.
|
|
33
|
Majid S, Dar AA, Saini S, Shahryari V,
Arora S, Zaman MS, Chang I, Yamamura S, Chiyomaru T, Fukuhara S, et
al: MicroRNA-1280 inhibits invasion and metastasis by targeting
ROCK1 in bladder cancer. PLoS One. 7:e467432012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gotoda T, Yamamoto H and Soetikno RM:
Endoscopic submu-cosal dissection of early gastric cancer. J
Gastroenterol. 41:929–942. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kosuke N, Oguma H and Yamamoto M: Early
gastric cancer with lymph node metastasis. Ann Surg. 253:840–841.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kim BS, Cho SW, Min SK and Lee BH:
Differences in prognostic factors between early and advanced
gastric cancer. Hepatogastroenterology. 58:1032–1040.
2011.PubMed/NCBI
|
|
37
|
Lai IR, Lee WJ, Huang MT and Lin HH:
Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in
gastric cancer patients and correlation with recurrence.
Hepatogastroenterology. 49:1157–1160. 2002.PubMed/NCBI
|
|
38
|
Gao F, Chang J, Wang H and Zhang G:
Potential diagnostic value of miR-155 in serum from lung
adenocarcinoma patients. Oncol Rep. 31:351–357. 2014.
|
|
39
|
Sun Y, Wang M, Lin G, Sun S, Li X, Qi J
and Li J: Serum microRNA-155 as a potential biomarker to track
disease in breast cancer. PLoS One. 7:e470032012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chu Y, Ouyang Y, Wang F, Zheng A, Bai L,
Han L, Chen Y and Wang H: MicroRNA-590 promotes cervical cancer
cell growth and invasion by targeting CHL1. J Cell Biochem.
115:847–853. 2014. View Article : Google Scholar
|
|
41
|
Ma Y, Qin H and Cui Y: miR-34a targets
GAS1 to promote cell proliferation and inhibit apoptosis in
papillary thyroid carcinoma via PI3K/Akt/Bad pathway. Biochem
Biophys Res Commun. 441:958–963. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Meng S, Cao J, Zhang X, Fan Y, Fang L,
Wang C, Lv Z, Fu D and Li Y: Downregulation of microRNA-130a
contributes to endothelial progenitor cell dysfunction in diabetic
patients via its target Runx3. PLoS One. 8:e686112013. View Article : Google Scholar : PubMed/NCBI
|
